Page 1 | Search Results | Molecular Cancer Therapeutics | American Association for Cancer Research

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Abstract PR006: Initial results from first-in-human study of AMG 193, an MTA-cooperative PRMT5 inhibitor, in biomarker-selected solid tumors

Mol Cancer Ther (2023) 22 (12_Supplement): PR006.

https://doi.org/10.1158/1535-7163.TARG-23-PR006

Published: 01 December 2023

View article titled, Abstract PR006: Initial results from first-in-human study of AMG 193, an MTA-cooperative PRMT5 inhibitor, in biomarker-selected solid tumors

Journal Articles

Abstract C047: A phase Ia/Ib, dose-escalation/expansion study of BI 907828, an MDM2-p53 antagonist, in combination with BI 754091, an anti-PD-1 antibody, and BI 754111, an anti-LAG-3 antibody, in patients with advanced solid tumors

Anthony Tolcher, Navid Hafez, Noboru Yamamoto, Jaehong Park, Rolf Grempler, Anthony Lucarelli, Markus P Vallaster, Bushi Wang, David Hyman

Mol Cancer Ther (2019) 18 (12_Supplement): C047.

https://doi.org/10.1158/1535-7163.TARG-19-C047

Published: 01 December 2019

View article titled, Abstract C047: A phase Ia/Ib, dose-escalation/expansion study of BI 907828, an MDM2-p53 antagonist, in combination with BI 754091, an anti-PD-1 antibody, and BI 754111, an anti-LAG-3 antibody, in patients with advanced solid tumors

Journal Articles

First-in-Human Phase I Study of an Oral HSP90 Inhibitor, TAS-116, in Patients with Advanced Solid Tumors

Akihiko Shimomura, Noboru Yamamoto, Shunsuke Kondo, Yutaka Fujiwara, Shigenobu Suzuki, Noriko Yanagitani, Atsushi Horiike, Satoru Kitazono, Fumiyoshi Ohyanagi, Toshihiko Doi, Yasutoshi Kuboki, Akihito Kawazoe, Kohei Shitara, Izumi Ohno, Udai Banerji, Raghav Sundar, Shuichi Ohkubo, Elizabeth M. Calleja, Makoto Nishio

Mol Cancer Ther (2019) 18 (3): 531–540.

https://doi.org/10.1158/1535-7163.MCT-18-0831

Published: 01 March 2019

View article titled, First-in-Human Phase I Study of an Oral HSP90 Inhibitor, TAS-116, in Patients with Advanced Solid Tumors

Journal Articles

Abstract A204: INCB024360 (Epacadostat) monotherapy and in combination with pembrolizumab in patients with advanced solid tumors: primary results from first-in-Japanese phase I study (KEYNOTE-434)

Yutaka Fujiwara, Kohei Shitara, Toshio Shimizu, Kan Yonemori, Nobuaki Matsubara, Izumi Ohno, Takahiro Kogawa, Yoichi Naito, Lance Leopold, Kahori Sasahara, Naoyoshi Yatsuzuka, Tomoko Takami, Takashi Shimamoto, Noboru Yamamoto, Toshihiko Doi

Mol Cancer Ther (2018) 17 (1_Supplement): A204.

https://doi.org/10.1158/1535-7163.TARG-17-A204

Published: 01 January 2018

View article titled, Abstract A204: INCB024360 (Epacadostat) monotherapy and in combination with pembrolizumab in patients with advanced solid tumors: primary results from first-in-Japanese phase I study (KEYNOTE-434)

Journal Articles

Abstract B160: First-in-human phase 1 study of E7090, a novel selective inhibitor of FGFRs, in patients with advanced solid tumors

Takafumi Koyama, Toshio Shimizu, Satoru Iwasa, Yutaka Fujiwara, Shunsuke Kondo, Shigehisa Kitano, Kan Yonemori, Akihiko Shimomura, Sakura Iizumi, Tatsuya Sasaki, Junji Furuse, Noboru Yamamoto

Mol Cancer Ther (2018) 17 (1_Supplement): B160.

https://doi.org/10.1158/1535-7163.TARG-17-B160

Published: 01 January 2018

View article titled, Abstract B160: First-in-human phase 1 study of E7090, a novel selective inhibitor of FGFRs, in patients with advanced solid tumors

Journal Articles

Abstract A165: Result of a phase 1 (dose-escalation stage), first-in-human study of ASP5878, an oral FGFR inhibitor, in patients with advanced solid tumors

Toshio Shimizu, Toshihiko Doi, Noboru Yamamoto, Haruyasu Murakami, Junji Furuse, Koji Kawai, Hiroyuki Nishiyama, Satoshi Morita, Shunji Takahashi, Erkut Bahceci, Joyce Steinberg, Howard A. Ball, Futoshi Kunieda, Kentaro Takeda, Aya Kita, Shigeru Takeshita

Mol Cancer Ther (2015) 14 (12_Supplement_2): A165.

https://doi.org/10.1158/1535-7163.TARG-15-A165

Published: 01 December 2015

View article titled, Abstract A165: Result of a phase 1 (dose-escalation stage), first-in-human study of ASP5878, an oral FGFR inhibitor, in patients with advanced solid tumors

Journal Articles

Abstract B87: First-in-human phase I dose escalation study of TAS-116, a novel, orally active HSP90α and HSP90β selective inhibitor, in patients with advanced solid tumors

Akihiko Shimomura, Atsushi Horiike, Yuichi Tambo, Fumiyoshi Ohyanagi, Noriko Yanagitani, Satoru Kitazono, Yutaka Fujiwara, Yuko Tanabe, Shuichi Ohkubo, Noboru Yamamoto, Makoto Nishio

Mol Cancer Ther (2015) 14 (12_Supplement_2): B87.

https://doi.org/10.1158/1535-7163.TARG-15-B87

Published: 01 December 2015

View article titled, Abstract B87: First-in-human phase I dose escalation study of TAS-116, a novel, orally active HSP90α and HSP90β selective inhibitor, in patients with advanced solid tumors

Journal Articles

Abstract B179: Final results of a phase 1 study of cabozantinib (Cabo) in Japanese patients (pts) with expansion cohorts in non-small cell lung cancer (NSCLC) with defined molecular alterations

Hiroshi Nokihara, Makoto Nishio, Noboru Yamamoto, Yutaka Fujiwawa, Hidehito Horinouchi, Shintaro Kanda, Asushi Horiike, Fumiyoshi Ohyanagi, Yifah Yaron, Anne Borgman, Tomohide Tamura

Mol Cancer Ther (2015) 14 (12_Supplement_2): B179.

https://doi.org/10.1158/1535-7163.TARG-15-B179

Published: 01 December 2015

View article titled, Abstract B179: Final results of a phase 1 study of cabozantinib (Cabo) in Japanese patients (pts) with expansion cohorts in non-small cell lung cancer (NSCLC) with defined molecular alterations

Journal Articles

Abstract B188: A Phase l study of BYL719, an α-isoform selective PI3K inhibitor, in Japanese patients with advanced solid malignancies.

Yoshihito Kogure, Yasuhide Yamada, Hideo Saka, Chiyoe Kitagawa, Satoru Iwasa, Noboru Yamamoto, Takuji Aoki, Tomoyuki Kakizume, Matthew Robson, Cornelia Quadt, Ayako Mitsuma, Takashi Shibata, Yuichi Ando

Mol Cancer Ther (2013) 12 (11_Supplement): B188.

https://doi.org/10.1158/1535-7163.TARG-13-B188

Published: 01 November 2013

View article titled, Abstract B188: A Phase l study of BYL719, an α-isoform selective PI3K inhibitor, in Japanese patients with advanced solid malignancies.

Journal Articles

Abstract C68: Phase I study of administration of LY2523355, an Eg5 inhibitor, for 3 consecutive days every 3 weeks in Japanese patients with refractory solid tumors.

Yutaka Fujiwara, Hiroshi Nokihara, Noboru Yamamoto, Yasuhide Yamada, Hiroshi Wakui, Shinji Nakamichi, Hidenori Mizugaki, Satoru Kitazono, Hironori Kanda, Kohei Suzuki, Shiro Akinaga, Tomohide Tamura

Mol Cancer Ther (2013) 12 (11_Supplement): C68.

https://doi.org/10.1158/1535-7163.TARG-13-C68

Published: 01 November 2013

View article titled, Abstract C68: Phase I study of administration of LY2523355, an Eg5 inhibitor, for 3 consecutive days every 3 weeks in Japanese patients with refractory solid tumors.

Journal Articles

Abstract A67: Phase I study of HER3 targeted antibody patritumab (U3-1287) in combination with erlotinib in Japanese patients with non-small cell lung cancer (NSCLC).

Noboru Yamamoto, Atsushi Horiike, Makoto Nishio, Haruyasu Murakami, Nobuyuki Yamamoto, Hiroyasu Kaneda, Kazuhiko Nakagawa, Tomohide Tamura

Mol Cancer Ther (2013) 12 (11_Supplement): A67.

https://doi.org/10.1158/1535-7163.TARG-13-A67

Published: 01 November 2013

View article titled, Abstract A67: Phase I study of HER3 targeted antibody patritumab (U3-1287) in combination with erlotinib in Japanese patients with non-small cell lung cancer (NSCLC).

Journal Articles

Abstract C109: Association of TP53 gene polymorphism with response to platinum-based doublet chemotherapy in non-small cell lung cancer patients.

Kouya Shiraishi, Hideo Kunitoh, Chiharu Tanai, Yasushi Goto, Seiichiro Yamamoto, Hiroshi Nokihara, Noboru Yamamoto, Ikuo Sekine, Yuishiro Ohe, Tomohide Tamura, Jun Yokota, Takashi Kohno

Mol Cancer Ther (2011) 10 (11_Supplement): C109.

https://doi.org/10.1158/1535-7163.TARG-11-C109

Published: 12 November 2011

View article titled, Abstract C109: Association of TP53 gene polymorphism with response to platinum-based doublet chemotherapy in non-small cell lung cancer patients.

Journal Articles

Abstract C37: A Phase 1 open‐label study evaluating pharmacokinetics, safety, and tolerability of linifanib in Japanese patients with solid tumors

Tomohide Tamura, Noboru Yamamoto, Hiroshi Nokihara, Yasuhide Yamada, Hajime Asahina, Takashi Shibata, Yasushi Goto, Maki Tanioka, Yosuke Tamura, Yoshitaka Seki, Yi‐Lin Chiu, Neeraj Gupta, Dawn Carlson

Mol Cancer Ther (2009) 8 (12_Supplement): C37.

https://doi.org/10.1158/1535-7163.TARG-09-C37

Published: 10 December 2009

View article titled, Abstract C37: A Phase 1 open‐label study evaluating pharmacokinetics, safety, and tolerability of linifanib in Japanese patients with solid tumors

Journal Articles

Abstract B48: A phase 1 study of an antisense oligonucleotide against survivin (LY2181308) in Japanese patients with solid tumors

Hiroshi Nokihara, Noboru Yamamoto, Yasuhide Yamada, Kazuhiko Yamada, Yasushi Goto, Maki Tanioka, Yoshihiro Nambu, Kazunori Uenaka, Risa Sekiguchi, Tomohide Tamura

Mol Cancer Ther (2009) 8 (12_Supplement): B48.

https://doi.org/10.1158/1535-7163.TARG-09-B48

Published: 10 December 2009

View article titled, Abstract B48: A phase 1 study of an antisense oligonucleotide against survivin (LY2181308) in Japanese patients with solid tumors

Journal Articles

Phase I and pharmacokinetic study of ABI-007, a Cremophor^®-free nanoparticle formulation of paclitaxel, administered once every 3 weeks in Japanese patients with solid tumors.

Toru Mukohara, Hikaru Nakajima, Shunji Nagai, Hironobu Minami, Noboru Yamamoto, Kazuhiko Yamada, Yasuhide Yamada, Tomohide Tamura

Mol Cancer Ther (2007) 6 (11_Supplement): B75.

Published: 01 November 2007

View article titled, Phase I and pharmacokinetic study of ABI-007, a Cremophor<sup>®</sup>-free nanoparticle formulation of paclitaxel, administered once every 3 weeks in Japanese patients with solid tumors.

Journal Articles

Phase I study of cediranib, an oral, highly potent and selective VEGFR signaling inhibitor, in Japanese patients with advanced solid tumors

Noboru Yamamoto, Yasuhide Yamada, Kazuhiko Yamada, Hiroshi Nokihara, Yutaka Fujiwara, Taizo Hirata, Nobuyuki Yamamoto, Narikazu Boku, Eisei Shin, Tomohide Tamura

Mol Cancer Ther (2007) 6 (11_Supplement): A253.

Published: 01 November 2007

View article titled, Phase I study of cediranib, an oral, highly potent and selective VEGFR signaling inhibitor, in Japanese patients with advanced solid tumors

NARROW

Abstract PR006: Initial results from first-in-human study of AMG 193, an MTA-cooperative PRMT5 inhibitor, in biomarker-selected solid tumors

Abstract C047: A phase Ia/Ib, dose-escalation/expansion study of BI 907828, an MDM2-p53 antagonist, in combination with BI 754091, an anti-PD-1 antibody, and BI 754111, an anti-LAG-3 antibody, in patients with advanced solid tumors

First-in-Human Phase I Study of an Oral HSP90 Inhibitor, TAS-116, in Patients with Advanced Solid Tumors

Abstract A204: INCB024360 (Epacadostat) monotherapy and in combination with pembrolizumab in patients with advanced solid tumors: primary results from first-in-Japanese phase I study (KEYNOTE-434)

Abstract B160: First-in-human phase 1 study of E7090, a novel selective inhibitor of FGFRs, in patients with advanced solid tumors

Abstract A165: Result of a phase 1 (dose-escalation stage), first-in-human study of ASP5878, an oral FGFR inhibitor, in patients with advanced solid tumors

Abstract B87: First-in-human phase I dose escalation study of TAS-116, a novel, orally active HSP90α and HSP90β selective inhibitor, in patients with advanced solid tumors

Abstract B179: Final results of a phase 1 study of cabozantinib (Cabo) in Japanese patients (pts) with expansion cohorts in non-small cell lung cancer (NSCLC) with defined molecular alterations

Abstract B188: A Phase l study of BYL719, an α-isoform selective PI3K inhibitor, in Japanese patients with advanced solid malignancies.

Abstract C68: Phase I study of administration of LY2523355, an Eg5 inhibitor, for 3 consecutive days every 3 weeks in Japanese patients with refractory solid tumors.

Abstract A67: Phase I study of HER3 targeted antibody patritumab (U3-1287) in combination with erlotinib in Japanese patients with non-small cell lung cancer (NSCLC).

Abstract C109: Association of TP53 gene polymorphism with response to platinum-based doublet chemotherapy in non-small cell lung cancer patients.

Abstract C37: A Phase 1 open‐label study evaluating pharmacokinetics, safety, and tolerability of linifanib in Japanese patients with solid tumors

Abstract B48: A phase 1 study of an antisense oligonucleotide against survivin (LY2181308) in Japanese patients with solid tumors

Phase I and pharmacokinetic study of ABI-007, a Cremophor^®-free nanoparticle formulation of paclitaxel, administered once every 3 weeks in Japanese patients with solid tumors.

Phase I study of cediranib, an oral, highly potent and selective VEGFR signaling inhibitor, in Japanese patients with advanced solid tumors

Email alerts

AACR Journals

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only